BioPharmSignal logoBioPharmSignal

Biotech News

ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026

Oric Pharmaceuticals, Inc. (ORIC)Oric Pharmaceuticals, Inc.Conference / presentation

Conference call and webcast to take place on Friday, October 23, 2026, at 8:00 a.m. ET Event to feature Dr. Joshua Sabari to discuss enozertinib clinical data and the potential of enozertinib to treat first-line NSCLC patients with EGFR atypical mutations SOUTH SAN FRANCISCO, Calif.

Related news

ORICOric Pharmaceuticals, Inc.2026-10-23 07:15 EST

ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026

ORICOric Pharmaceuticals, Inc.2026-10-23 07:15 EST

ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial

ZNTLZentalis2026-10-18 22:05 EST

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

SNDXSyndax Pharmaceuticals2026-11-04 14:01 EST

Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026

CHRSCoherus BioSciences, Inc.2026-10-14 20:30 EST

Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

MMSIMerit Medical2026-11-05 14:25 EST

Merit Medical Presents Real-World Data from the AVF Cohort of the WRAP Global Registry

BMEABiomea Fusion2026-10-12 20:30 EST

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

STROSutro Biopharma2026-10-12 12:00 EST

Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference

EXELExelixis2026-11-03 21:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

PRLDPrelude Therapeutics2026-10-16 20:01 EST

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

View all latest news

Oric Pharmaceuticals, Inc.

Oncology Resistance Biology ORIC Pharmaceuticals develops therapies intended to overcome mechanisms of treatment resistance in cancer. Its programs target epigenetic and signaling pathways that allow tumors to adapt to standard treatments. Rinzimetostat Rinzimetostat is an allosteric EED inhibitor that suppresses PRC2 activity. It is...

Recent company news

ORICOric Pharmaceuticals, Inc.2026-11-06 21:30 EST

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORICOric Pharmaceuticals, Inc.2026-11-03 21:01 EST

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

ORICOric Pharmaceuticals, Inc.2026-10-23 07:15 EST

ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial

ORICOric Pharmaceuticals, Inc.2026-10-23 07:15 EST

ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026

ORICOric Pharmaceuticals, Inc.2026-10-19 12:00 EST

ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026

Stock data

Close
8.49 USD
Market cap
788.8M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States